[1]石 磊,孙新增,李宝山,等.Ⅱ、Ⅲ期结肠癌患者辅助化疗XELOX方案、FOLFOX方案的临床疗效、不良反应及生活质量对比[J].医学信息,2018,31(13):68-72.[doi:10.3969/j.issn.1006-1959.2018.13.020]
　SHI Lei,SUN Xin-zeng,LI Bao-shan,et al.Clinical Efficacy,Adverse Reactions and Quality of Life of Adjuvant Chemotherapy XELOX and FOLFOX in Patients with Stage II and III Colon Cancer[J].Journal of Medical Information,2018,31(13):68-72.[doi:10.3969/j.issn.1006-1959.2018.13.020]
点击复制

Ⅱ、Ⅲ期结肠癌患者辅助化疗XELOX方案、FOLFOX方案的临床疗效、不良反应及生活质量对比()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年13期
页码:
68-72
栏目:
论著
出版日期:
2018-07-01

文章信息/Info

Title:
Clinical Efficacy,Adverse Reactions and Quality of Life of Adjuvant Chemotherapy XELOX and FOLFOX in Patients with Stage II and III Colon Cancer
文章编号:
1006-1959（2018）13-0068-05
作者:
石 磊; 孙新增; 李宝山; 白建平
解放军第二五四医院普通外科, 天津 300143
Author(s):
SHI Lei; SUN Xin-zeng; LI Bao-shan; BAI Jian-ping
Department of General Surgery,the 254 Hospital of PLA,Tianjin 300143,China
关键词:
结肠癌; 卡培他滨; 奥沙利铂; 氟尿嘧啶
Keywords:
Key words：Colon cancer; Capecitabine; Oxaliplatin; Fluorouracil
分类号:
R735.3
DOI:
10.3969/j.issn.1006-1959.2018.13.020
文献标志码:
A
摘要:
目的 比较辅助化疗XELOX方案、FOLFOX方案对Ⅱ、Ⅲ期结肠癌患者的临床疗效、不良反应及生活质量的差异。方法 收集2009年1月~2012年1月解放军第二五四医院普通外科收治的行根治性手术切除的171例结肠癌患者的临床资料，按数字随机分为两组，90例患者术后接受XELOX化疗方案，81例接受FOLFOX化疗方案。比较两组患者的无病生存期、5年生存率、不良反应发生及生存质量的差异。结果 XELOX组34例（37.78%）出现病情进展，FOLFOX组28例（34.57%）出现病情进展。XELOX组、FOLFOX组的3年无病生存率对比，差异无统计学意义（P＞0.05）。XELOX组死亡21例（23.33%）。FOLFOX组死亡19例（23.46%）。Log-rank检验结果显示，两组患者5年生存率对比，差异无统计学意义（P＞0.05）。两组患者恶性呕吐、高胆红血症的不良反应发生率，差异无统计学意义（P＞0.05）。神经毒性、腹泻、白细胞减少、粒细胞减少、血小板减少、口腔黏膜炎的发生率，FOLFOX组高于XELOX组，差异有统计学意义（P＜0.05）。XELOX组手足综合征的发生率高于XELOX组，差异有统计学意义（P＜0.05）。两组患者在化疗的不同阶段，情绪状况、功能状况、身体状况、社会/家庭状况、总体生存质量等5个纬度，差异均无统计学意义（P＞0.05）。 结论 对Ⅱ、Ⅲ期结肠癌患者而言，XELOX方案与FOLFOX方案在提高术后无病生存期、5年生存率及生活质量方面无明显差异。但XELOX方案不良反应更少，患者的依从性与耐受性更好。
Abstract:
Abstract：Objective To compare the clinical efficacy, adverse reactions and quality of life of patients with stage II and III colon cancer by XELOX and FOLFOX.Methods The clinical data of 171 patients with colon cancer who underwent radical surgery for general surgery in the 254th Hospital of Chinese People's Liberation Army from January 2009 to January 2012 were collected.They were randomly divided into two groups according to the number.90 patients received XELOX chemotherapy after operation and 81 patients received FOLFOX chemotherapy.The disease-free survival,5-year survival rate,adverse reaction occurrence and quality of life were compared between the two groups.Results In the XELOX group,34 patients(37.78%)developed disease progression,and 28 patients(34.57%)in the FOLFOX group developed disease progression.There was no significant difference in the 3-year disease-free survival rate between the XELOX group and the FOLFOX group(P>0.05).21 patients(23.33%)died in the XELOX group.19 patients (23.46%)died in the FOLFOX group.Log-rank test results showed that there was no significant difference in the 5-year survival rate between the two groups(P>0.05).There was no significant difference in the incidence of adverse reactions between malignant vomiting and hyperbilirubinemia between the two groups(P>0.05).The incidence of neurotoxicity,diarrhea,leukopenia,neutropenia, thrombocytopenia,and oral mucositis was higher in the FOLFOX group than in the XELOX group,the difference was statistically significant(P<0.05).The incidence of hand-foot syndrome in the XELOX group was higher than that in the XELOX group,and the difference was statistically significant(P<0.05).There were no significant differences in the five latitudes between the two groups at different stages of chemotherapy,such as emotional status,functional status,physical condition,social/family status,and overall quality of life(P>0.05).Conclusion For patients with stage II and III colon cancer,there is no significant difference between the XELOX regimen and the FOLFOX regimen in improving postoperative disease-free survival,5-year survival,and quality of life.However,the XELOX regimen has fewer side effects and better patient compliance and tolerance.

参考文献/References:

[1]Ge J,Zhu L,Zhou J,et al.Association between co-inhibitory molecule gene tagging single nucleotide polymorphisms and the risk of colorectal cancer in Chinese[J].Journal of Cancer Research&Clinical Oncology,2015,141(9):1533-1544. [2]Wu XM,Yang HG,Zheng BA,et al.Functional Genetic Variations at the microRNA Binding-Site in the CD44 Gene Are Associated with Risk of Colorectal Cancer in Chinese Populations[J].Plos One,2015,10(5):e0127557. [3]Xynos E,Gouvas N,Triantopoulou C,et al.Clinical practice guidelines for the surgical management of colon cancer:a consensus statement of the Hellenic and Cypriot Colorectal Cancer Study Group by the HeSMO[J].Annals of GastroenterologyQuarterly Publication of the Hellenic Society of Gastroenterology,2016,29(1):3-17. [4]Yoshii Y,Furukawa T,Aoyama H,et al.Regorafenib as a potential adjuvant chemotherapy agent in disseminated small colon cancer:Drug selection outcome of a novel screening system using nanoimprinting 3-dimensional culture with HCT116-RFP cells[J].International Journal of Oncology,2016,48(4):1477. [5]Ishibashi K,Kumamoto K,Koda K,et al.A phase II clinical study of mFOLFOX6 XELOX as adjuvant chemotherapy after curative resection of stage III colon cancer:The FACOS study[J].Annals of Cancer Research&Therapy,2016,24(1):17-22. [6]Yamada T,Koda K,Ishibashi K,et al.182PPhase II clinical trial of adjuvant chemotherapy with mFOLFOX6 XELOX for stage III colon cancer in Japanese subjects[J].Annals of Oncology,2015,26(suppl 9):55. [7]Zaniboni A,Lonardi S,Labianca R,et al.FOLFOX4 XELOX in stage II-III colon cancer: early survival data of the Italian Three Or Six Colon Adjuvant(TOSCA) trial[J].Annals of Oncology,2017,28(suppl_6). [8]Okada K,Sadahiro S,Saito G,et al.Postoperative Adjuvant Chemotherapy for Stage III Colon Cancer Drug Selection,Tolerability,and Safety in Clinical Practice[J].Gan to Kagaku Ryoho,2016,43(5):587-592. [9]De Gramont A,Boni C,Navarro M,et al.Oxaliplatin/5FU/LV in adjuvant colon cancer:Updated efficacy results of the MOSAIC trial,including survival,with a median follow-up of six years [J].Journal of Clinical Oncology,2007. [10]Tournigand C,Andre T,Bachet J,et al.FOLFOX4 as adjuvant therapy in elderly patients(pts)with colon cancer(CC):Subgroup analysis of the MOSAIC trial[J].Journal of Clinical Oncology,2010,28(15):3522. [11]Cremolini C,Moretto R,Masi G,et al.Safety profile of capecitabine as maintenance treatment after induction with XELOX or FOLFOX in metastatic colorectal cancer,patients[J].Annals of Oncology Official Journal of the European Society for Medical Oncology,2016,28(9):mdw208. [12]Chen M,May B H,Zhou I W,et al.Meta-Analysis of Oxaliplatin-Based Chemotherapy Combined With Traditional Medicines for Colorectal Cancer:Contributions of Specific Plants to Tumor Response[J].Integrative Cancer Therapies,2016,15(1):40. [13]Kogita A,Yoshioka Y,Sakai K,et al.Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis[J].Biochemical&Biophysical Research Communications,2015,458(1):52-56. [14]Murphy CC,Harlan LC,Warren JL,et al.Race and Insurance Differences in the Receipt of Adjuvant Chemotherapy Among Patients With Stage III Colon Cancer[J].Journal of Clinical Oncology,2015,33(23):2530-2536. [15]Bours MJ,Beijer S,Winkels RM,et al.Dietary changes and dietary supplement use,and underlying motives for these habits reported by colorectal cancer survivors of the Patient Reported Outcomes Following Initial Treatment and Long-Term Evaluation of Survivorship(PROFILES)registry[J].British Journal of Nutrition,2015,114(2):286-296.

相似文献/References:

[1]苏周荣,杜东霖,魏正强.左半结肠癌伴梗阻一期切除吻合策略研究[J].医学信息,2018,31(10):51.[doi:10.3969/j.issn.1006-1959.2018.10.016]
　SU Zhou-rong,DU Dong-lin,WEI Zheng-qiang.Strategy of One-stage Resection and Anastomosis for Left Colon Cancer with Obstruction[J].Journal of Medical Information,2018,31(13):51.[doi:10.3969/j.issn.1006-1959.2018.10.016]
[2]崔忠泽,何 双,路丽祯,等.基于生物信息学分析筛选结肠癌关键基因[J].医学信息,2022,35(10):1.[doi:10.3969/j.issn.1006-1959.2022.10.001]
　CUI Zhong-ze,HE Shuang,LU Li-zhen,et al.Screening Key Genes of Colon Cancer Based on Bioinformatics Analysis[J].Journal of Medical Information,2022,35(13):1.[doi:10.3969/j.issn.1006-1959.2022.10.001]
[3]王 超,范小华,张 力,等.下腔静脉畸形伴腹腔多脏器异位合并结肠癌1例[J].医学信息,2018,31(18):188.[doi:10.3969/j.issn.1006-1959.2018.18.062]
　WANG Chao,FAN Xiao-hua,ZHANG Li,et al.a Case of Inferior Vena Cava Malformation Associated with Multiple Abdominal Organ Ectopic Colon Cancer[J].Journal of Medical Information,2018,31(13):188.[doi:10.3969/j.issn.1006-1959.2018.18.062]
[4]胡平华,黄 勤,李志华.含卡培他滨方案一线或后线治疗晚期乳腺癌的效果对比[J].医学信息,2018,31(22):142.[doi:10.3969/j.issn.1006-1959.2018.22.041]
　HU Ping-hua,HUANG Qin,LI Zhi-hua.Comparison of the Efficacy of Capecitabine Regimen in the Treatment of Advanced Breast Cancer with First-line or Posterior Line Therapy[J].Journal of Medical Information,2018,31(13):142.[doi:10.3969/j.issn.1006-1959.2018.22.041]
[5]操利超,张核子,余晨笛,等.CLDN11在结肠癌中的预后价值及其作为潜在免疫治疗靶点的研究[J].医学信息,2022,35(14):10.[doi:10.3969/j.issn.1006-1959.2022.14.002]
　CAO Li-chao,ZHANG He-zi,YU Chen-di,et al.The Prognostic Value of CLDN11 in Colon Cancer and its Potential Immunotherapy Targets[J].Journal of Medical Information,2022,35(13):10.[doi:10.3969/j.issn.1006-1959.2022.14.002]
[6]黄富全.结合靶向药物综合治疗结肠癌肝及肝外转移术后7年1例报告[J].医学信息,2019,32(01):186.[doi:10.3969/j.issn.1006-1959.2019.01.061]
[7]葛菁茹,朱静雅,苏日新,等.以肺转移为首发表现的结肠癌预后分析[J].医学信息,2021,34(04):96.[doi:10.3969/j.issn.1006-1959.2021.04.025]
　GE Jing-ru,ZHU Jing-ya,SU Ri-xin,et al.Prognostic Analysis of Colon Cancer with Lung Metastasis as the First Manifestation[J].Journal of Medical Information,2021,34(13):96.[doi:10.3969/j.issn.1006-1959.2021.04.025]
[8]韩 猛,薛三宝,倪 丰.CT与MRI术前诊断结肠癌及评价术后复发的价值[J].医学信息,2021,34(21):175.[doi:10.3969/j.issn.1006-1959.2021.21.050]
　HAN Meng,XUE San-bao,NI Feng.Value of CT and MRI in Preoperative Diagnosis and Postoperative Recurrence of Colon Cancer[J].Journal of Medical Information,2021,34(13):175.[doi:10.3969/j.issn.1006-1959.2021.21.050]
[9]那文秀.奥沙利铂联合卡培他滨治疗晚期胃癌的疗效[J].医学信息,2020,33(06):144.[doi:10.3969/j.issn.1006-1959.2020.06.046]
　NA Wen-xiu.Efficacy of Oxaliplatin Combined with Capecitabine in the Treatment of Advanced Gastric Cancer[J].Journal of Medical Information,2020,33(13):144.[doi:10.3969/j.issn.1006-1959.2020.06.046]
[10]郭 雪,石学军.替吉奥与卡培他滨同步放疗治疗复发性结直肠癌疗效与安全性的Meta分析[J].医学信息,2020,33(07):71.[doi:10.3969/j.issn.1006-1959.2020.07.021]
　GUO Xue,SHI Xue-jun.Meta-analysis of the Efficacy and Safety of Simultaneous Therapy of Tegafur and Capecitabine for Recurrent Colorectal Cancer[J].Journal of Medical Information,2020,33(13):71.[doi:10.3969/j.issn.1006-1959.2020.07.021]

更新日期/Last Update: 2018-07-01